Two of these drugs are approved from age 12 for obesity. None is approved below that. One trial sits behind the approval. It ran 68 weeks, and it measured BMI, not growth, not puberty and not bone.
You are probably here for one of two reasons. A prescriber has raised this for your twelve-year-old, or your teenager has asked you about the drug their friend is on. Either way the question is the same: are these drugs safe for kids, and what is actually known. The answer is the same either way. This is better evidenced than almost anything else on this site, and it is still thinner than the decision in front of you.
October 2026 brought two of them. The World Health Organization published its first global guidelines on child and adolescent obesity, and they draw a hard line at age 10.1 A study of more than 3.5 million American children aged 8 to 11 reported a 310-fold rise in prescriptions since 2019.2 Side by side they look alarming. They are less alarming than that once you know what each one counts.
Which GLP-1 drugs are approved for teenagers, and from what age?
Only two carry a paediatric indication. Both start at age 12.
| Product | Approved age | Indication | Approved |
|---|---|---|---|
| Wegovy injection (semaglutide 2.4 mg) | 12 and older | Obesity | December 23, 20223 |
| Saxenda (liraglutide 3.0 mg) | 12 to 17 | Obesity | December 4, 20204 |
| Wegovy tablets | Adults only | Weight reduction, cardiovascular risk | |
| Zepbound (tirzepatide) | Adults only | Obesity, obstructive sleep apnoea |
That table catches people out in three places. The Wegovy injection is approved from 12 and the Wegovy tablet is not, so two products sharing a brand name have different approved populations. Zepbound has no paediatric indication at all, for either of its uses, so a teenager on tirzepatide is taking it off-label. The same goes for the diabetes-branded versions of these molecules, Ozempic and Mounjaro, neither of which carries a paediatric weight indication. Wegovy's own cardiovascular and liver indications are also adult-only even though its obesity indication is not.
If your child is under 12, nothing in this class is approved for weight anywhere in the world.
What did the adolescent trial actually measure?
It measured BMI over 68 weeks in 201 young people.
STEP TEENS was a multinational, double-blind, placebo-controlled phase 3a trial at 37 sites, running from October 2019 to March 2022. It randomised 201 adolescents aged 12 to under 18 in a 2 to 1 ratio, 134 to semaglutide and 67 to placebo, all with a BMI at the 95th percentile or above, or at the 85th percentile or above with a weight-related condition. Treatment ran 68 weeks alongside a lifestyle intervention, with follow-up to week 75.5
| Outcome at week 68 | Semaglutide | Placebo |
|---|---|---|
| Mean change in BMI | −16.1% | +0.6% |
| Lost at least 5% of body weight | 73% (95 of 131) | 18% (11 of 62) |
| Nausea | 42% (56 of 133) | 18% (12 of 67) |
| Vomiting | 36% (48 of 133) | 10% (7 of 67) |
| Stopped for an adverse event | 5% (6) | 4% (3) |
| Acute gallbladder disease | 4% (5), all with gallstones | 0 |
That headline figure is a BMI change and not a weight change. The two can move apart in a growing adolescent, because a child who gains height while holding weight steady has a falling BMI. Coverage that reported "16% weight loss" in teenagers was describing the wrong quantity.
Two results get less attention than they should. Vomiting affected more than a third of the treated group. That is a high rate even for this class. Five adolescents on semaglutide also developed acute gallbladder disease with gallstones inside 68 weeks, against none on placebo. Gallstones after rapid weight loss are a known effect in adults. In a 134-person adolescent arm, five cases of gallstones belongs in the conversation with a prescriber.
The authors name their own limits. A longer treatment period "would have provided insight into the durability of the effect," the follow-up was too short to monitor what stopping does, and weight was already returning between weeks 68 and 75. The trial population skewed female with few participants from several racial and ethnic groups, and the authors say that limits generalisability.5
Are children under 12 being prescribed these drugs?
A small number are. The two figures describing it pull in opposite directions.
A study of more than 3.5 million American children aged 8 to 11 with obesity found that prescriptions rose 310-fold between 2019 and 2026. Across that cohort, 0.6% received a GLP-1 prescription.2
Both figures are true and they answer different questions. A 310-fold rise from a near-zero base is still a small number, and the cohort is children who already have obesity rather than children in general. What the data shows is a move from almost never to rarely.
The study's author has written about it separately, and his position complicates both headlines. He gives the 0.6% figure and says, "This number is too low." He also writes that broader use in younger children "is not justified without long-term data on how these medications impact growth and puberty."6 Those two statements sit together, from the same researcher, and anyone quoting one of them should know the other exists.
What do the WHO guidelines say?
The guidance arrives as two documents and draws a hard line at age 10.
The October 2026 release is not one guideline but two, one covering children and one covering adolescents.1
For children aged 0 to 9, WHO "does not recommend pharmacological treatment, bariatric surgery" or "weight-loss devices."1 That is a recommendation against, not an absence of guidance.
For adolescents aged 10 to 19, "treatment with approved medicines may be considered only when a supervized multimodal lifestyle programme has not achieved the desired results."1
Read the sentence closely and two phrases do the work. "Only when" makes medication a step after something else has been tried, not an option alongside it. And "approved medicines" excludes everything this site's price data tracks, because research-labelled vials are not approved medicines in any country.
What does the American guideline say, and does it agree with WHO?
It lands on the same age as WHO and disagrees about when the drug comes in.
The American Academy of Pediatrics published its clinical practice guideline on childhood and adolescent obesity in Pediatrics in 2023. On medication its position is that clinicians should offer weight-loss pharmacotherapy as an adjunct to health behaviour and lifestyle treatment for adolescents aged 12 years or older with obesity, and that adolescents aged 13 or older with severe obesity should be evaluated for metabolic and bariatric surgery.9
Set that beside WHO. Both land on age 12 to 13 as the threshold, and they differ on sequence. WHO says approved medicines may be considered "only when" a supervised programme "has not achieved the desired results".1 That puts the drug after the programme has been tried and found wanting. The AAP frames medication as an adjunct to lifestyle treatment, putting the two together from the start.
That difference decides what a reasonable prescriber does with a twelve-year-old who has just been diagnosed. If your clinician is working from the AAP guideline and you have read the WHO coverage, the apparent disagreement is real and it is about sequencing rather than about whether these drugs belong in paediatrics at all.
What is the lifestyle programme that comes first?
It is a serious commitment of hours, and most families are never offered the real version.
Both guidelines place medication alongside or after something they call intensive lifestyle treatment, and neither headline explains what that involves. The AAP guideline does. Its definition states that this treatment "is most often effective when it occurs face-to-face, engages the whole family, and delivers at least 26 hours" of contact, and that it "is foundational" and "should continue longitudinally."9
That is a serious programme, far more than a dietitian appointment and a follow-up. Ask what is actually on offer before accepting that the lifestyle route has been exhausted, because in many places it has not been attempted at the intensity either guideline describes.
What is known about growth, puberty and bone?
Less than the question deserves. The gap is a specific one.
STEP TEENS reported BMI, body weight, waist circumference and metabolic measures. Its authors' stated limitations concern durability and generalisability.5 Growth velocity, height, pubertal staging and bone density are not among the outcomes the trial is reported on. Bone mineral density in particular has not been measured in an adolescent trial of these drugs.
That gap is named on the record by the researcher behind the under-12 prescribing study, who writes that broader use in younger children is not justified without long-term data on how these medications impact growth and puberty.6 A researcher who has just published the largest study of paediatric prescribing saying the growth and puberty data is missing is about as authoritative as an absence gets.
Why this matters more in a teenager than in an adult: adolescence is when most adult bone mass is laid down and when the growth plates are still open, and neither window reopens. Final adult height is settled in those years. A drug tested for 68 weeks may be taken for years in practice, across exactly that period, and the trials were not built to see it. Our guide on peptides under 25 covers growth plate closure in more detail, for a different set of compounds.
Do teenagers on these drugs get nutritional deficiencies?
One study has looked. Its headline figure needs unpacking.
A retrospective analysis of Inovalon administrative claims from 2017 to 2022, covering over 100 million patients, identified 2,031 GLP-1 users aged 10 to 17 and followed them for up to a year after starting. Within that year, 16.88% received a diagnosis of at least one nutritional deficiency or deficiency-related complication.7
Vitamin D deficiency accounted for 12.4% of that, with nutritional anaemia at 1.55% and iron-deficiency anaemia at 1.44%.7 So roughly three-quarters of the headline figure is vitamin D. Vitamin D deficiency is common in adolescents generally and is not specific to this drug class.
The authors are explicit that the analysis "does not permit causal inference," and they note that claims codes may under-report deficiencies that never got diagnosed.7 The data also runs only to 2022, before most of the prescribing rise this page describes.
The sturdiest number in the paper is not about deficiency at all. Only 23.3% of these adolescents had a nutrition counselling visit within 180 days of starting, with a mean of 149 days to the first visit.7 Whatever the deficiency numbers mean, three-quarters of them started an appetite-suppressing drug without seeing anyone about food within six months.
What happens when a teenager stops?
Nobody has studied it properly. The one clue available is not encouraging.
STEP TEENS followed participants for seven weeks past the end of treatment, and the authors report weight regain during that window.5 Seven weeks is not a study of stopping, and the authors say so.
That leaves you with an open question and no trial behind it. A drug started at 13 is either taken for years or stopped at some point, and no published trial describes what happens to a young person's weight, growth or eating after they come off.
Will insurance cover it for a teenager?
That depends on the plan, and the approved indication is what the decision turns on.
Coverage for anti-obesity medication varies by plan more than almost any other drug class, and a dependent on a family policy is not automatically covered just because the plan covers an adult. The thing to ask the plan directly is whether it covers anti-obesity medication for dependents, and at what age.
Where the approval age matters is off-label use. A prescription for Wegovy injection at 13 is within the approved indication. A prescription for Zepbound at 13, or for anything at 11, is outside it, and plans are generally less willing to pay for off-label use in a child than for an approved one. That is also the point at which families start looking at cash prices, and the last section of this page covers where that leads.
Our guide on what peptide therapy actually costs and our guide on paying with an HSA or FSA cover the mechanics. Neither is specific to adolescents, and the age question is one only your plan can answer.
When does this need a doctor rather than a search?
Intrusive thinking about food, restriction and eating disorders all sit close to this subject, and adolescence is when eating disorders most often start.
A medication that reduces appetite can hide under-eating instead of treating it. That is true at any age, and it matters more in a body that is still growing. A teenager who is not eating enough carries consequences an adult does not.
Raise these with a clinician instead of working them out at home: eating that comes with guilt, secrecy or hiding food; weight falling faster than the prescriber expected; periods becoming irregular or stopping; dizziness, feeling cold, hair thinning or fatigue that does not resolve; or relief at not eating that starts to feel like the goal.
If any of that is familiar, the National Alliance for Eating Disorders runs a helpline staffed by clinicians, and a paediatrician or prescriber can refer. If a young person is in crisis, in the US the 988 Suicide and Crisis Lifeline takes calls and texts.
Nothing on this page is a reason to change or stop a prescription. That conversation belongs with whoever wrote it.
What about buying these online?
Do not. This is the one question on the page with an unambiguous answer.
Semaglutide is widely available from research-labelled sellers. In our October 10 capture, it appeared in 179 listings across 85 sellers at a median of $7.00 per mg.8 That is far below the cost of a prescription, and that is exactly why people consider it.
Everything above describes a different situation. STEP TEENS used a pharmaceutical product at a known dose, in adolescents who were screened, monitored for 68 weeks, and had gallbladder disease caught when it happened. The WHO guidance that permits medication for a 15-year-old specifies "approved medicines," after a supervised programme, with supervision continuing.1
A research vial has no approved paediatric indication, no prescriber, no monitoring and no verified contents. For a child still growing, in the window when bone mass is laid down, with no trial describing what the drug does to growth or puberty over years, it is the worst version of a decision that is already difficult with a prescription in hand. Our guide on what research-use-only actually means covers the legal side, and our vendor vetting guide covers the rest.
Common questions
Can a 12-year-old take Wegovy?
The Wegovy injection is approved in the US for adults and paediatric patients aged 12 and older with obesity, approved for that age group on December 23, 2022. Wegovy tablets are approved for adults only. Whether it is appropriate for a particular twelve-year-old is a decision for a prescriber, and WHO guidance places medication after a supervised lifestyle programme rather than alongside it.
Are GLP-1 drugs approved for teenagers?
Two are. The Wegovy injection from age 12 and Saxenda from 12 to 17, both for obesity. Zepbound has no paediatric indication for either of its uses, and no GLP-1 drug is approved below age 12 for weight.
Are GLP-1s safe during puberty?
No trial has measured it. The adolescent trial behind the approval reported BMI, weight, waist circumference and metabolic measures over 68 weeks, and growth velocity, pubertal staging and bone mineral density are not among its reported outcomes. The researcher behind the largest paediatric prescribing study has said broader use in younger children is not justified without long-term data on growth and puberty.
How much weight did teenagers lose in the trial?
The reported figure is a 16.1% mean reduction in BMI at week 68 against a 0.6% increase on placebo. That is a BMI change and not a weight change. 73% of the semaglutide group lost at least 5% of body weight, against 18% on placebo.
What are the side effects of GLP-1 drugs in teenagers?
The side effects reported in STEP TEENS were mainly gastrointestinal. Nausea affected 42% on semaglutide against 18% on placebo, and vomiting 36% against 10%. Five participants, 4% of the semaglutide group, developed acute gallbladder disease with gallstones, against none on placebo. 5% stopped for an adverse event, against 4% on placebo.
Do GLP-1 drugs cause nutritional deficiencies in teenagers?
One claims-based study of 2,031 users aged 10 to 17 found 16.88% diagnosed with a nutritional deficiency or related complication within a year, of which vitamin D accounted for 12.4%. The authors state the analysis does not permit causal inference. The clearer finding is that only 23.3% had a nutrition counselling visit within 180 days of starting.
Does the American guideline agree with the WHO guidance?
They agree on the age threshold and differ on sequence. The AAP guideline frames weight-loss medication as an adjunct to health behaviour and lifestyle treatment for adolescents aged 12 or older with obesity. WHO says approved medicines may be considered only when a supervised multimodal lifestyle programme has not achieved the desired results. One puts the drug alongside the programme, the other after it.
What counts as the lifestyle programme that comes before medication?
The AAP guideline defines intensive health behaviour and lifestyle treatment as most effective when delivered face-to-face, engaging the whole family, and providing at least 26 hours of contact, continuing over time. That is considerably more than a single dietitian appointment. Ask what is on offer before accepting that the lifestyle route has been tried.
What does the WHO say about weight-loss drugs for children?
For children aged 0 to 9, WHO does not recommend pharmacological treatment, bariatric surgery or weight-loss devices. For adolescents aged 10 to 19, approved medicines may be considered only when a supervised multimodal lifestyle programme has not achieved the desired results.
How many children under 12 are on GLP-1 drugs?
In a cohort of more than 3.5 million American children aged 8 to 11 with obesity, 0.6% received a prescription, after a 310-fold rise since 2019. Both figures describe the same data: a move from almost never to rarely, within a group that already has obesity.
Does the weight come back if a teenager stops?
No trial has studied stopping properly. STEP TEENS followed participants seven weeks past the end of treatment and reported weight returning in that window, and its authors say the follow-up was too short to monitor the effect of withdrawal.
Does insurance cover GLP-1 drugs for teenagers?
That depends entirely on the plan. Coverage for anti-obesity medication varies widely, and a dependent is not automatically covered because an adult on the same policy is. Ask the plan whether it covers anti-obesity medication for dependents and from what age. Off-label use is generally harder to get covered than an approved indication, and that includes any of these drugs below age 12 and Zepbound at any age under 18.
Can GLP-1 drugs affect a teenager's height or growth plates?
No trial has measured it. The adolescent trial behind the approval reported BMI, weight, waist circumference and metabolic outcomes, and growth velocity, height, pubertal staging and bone density are not among them. Adolescence is when growth plates close and most adult bone mass is laid down, so the absence of data matters more at this age than in adults.
Is it legal to buy semaglutide for a teenager without a prescription?
Research-labelled vials are not approved medicines and carry no paediatric indication, no prescriber and no verified contents. Our guide on what "research use only" actually means covers the legal position.
Sources
- World Health Organization. WHO issues first global guidelines on child and adolescent obesity, and the accompanying guidelines on the integrated management of obesity in children and in adolescents. October 7, 2026. who.int, guideline who.int/publications. Announcement and guideline landing pages read at source; the full 133-page guideline PDF was not retrieved, so no recommendation strength or certainty-of-evidence rating is quoted here. Two separate guidelines were issued, one for children and one for adolescents. For children aged 0 to 9 WHO "does not recommend pharmacological treatment, bariatric surgery" or "weight-loss devices for children aged 0-9 years." For adolescents aged 10 to 19, "treatment with approved medicines may be considered only when a supervized multimodal lifestyle programme" "has not achieved the desired results." The guidelines cover dietary interventions, physical activity, behaviour change, digital health, pharmacotherapy, bariatric surgery and multimodal interventions.
- Trends in GLP-1 Receptor Agonist Prescriptions for Children Ages 8 to 11 With Obesity: 2019-2026. Pediatrics, 2026. DOI 10.1542/peds.2026-077048. publications.aap.org. Figures taken from the senior author's own account of the study in STAT, cited below, because the journal page would not load. More than 3.5 million children aged 8 to 11 with obesity; 0.6% received a GLP-1 prescription; a 310-fold increase since 2019. The study design, data source and end year were not confirmed from the paper itself.
- Wegovy (semaglutide injection) FDA approval history and current indications. drugs.com. Read at source. "FDA Approves Once-Weekly Wegovy injection for the Treatment of Obesity in Teens Aged 12 Years and Older", December 23, 2022. Current labelled population for weight reduction and long-term weight maintenance: "adults and pediatric patients aged 12 years and older with obesity", plus adults with overweight and at least one weight-related comorbidity. Cardiovascular risk reduction and the MASH indication are adult-only. Wegovy Tablets are adult-only. Cited via a drug-information database rather than the FDA label PDF, since the label PDF would not load.
- Saxenda (liraglutide) FDA approval history. drugs.com. Read at source. "FDA Approves Saxenda (liraglutide) for the Treatment of Obesity in Adolescents Aged 12-17", December 4, 2020. Cited via a drug-information database because the FDA label PDF would not load.
- Weghuber D, et al. Once-Weekly Semaglutide in Adolescents with Obesity (STEP TEENS). New England Journal of Medicine, 2022. PMC9997064, journal version nejm.org. Full text read at source. Multinational, double-blind, parallel-group, randomised, placebo-controlled phase 3a trial at 37 sites, October 2019 to March 2022. 201 participants randomised 2:1, 134 semaglutide and 67 placebo. Adolescents aged 12 to under 18 with BMI at or above the 95th percentile, or at or above the 85th percentile with at least one weight-related coexisting condition. 68 weeks of treatment plus lifestyle intervention, with follow-up to week 75. Mean percentage change in BMI at week 68, treatment policy estimand: semaglutide −16.1%, placebo +0.6%; between-group difference −16.7 percentage points, 95% CI −20.3 to −13.2. At least 5% weight loss: 73% (95 of 131) against 18% (11 of 62). Nausea 42% (56 of 133) against 18% (12 of 67); vomiting 36% (48 of 133) against 10% (7 of 67). Discontinuation for adverse events 5% (6) against 4% (3). Five participants (4%) on semaglutide had acute gallbladder disease, all with cholelithiasis and one also with cholecystitis; no placebo participants had cholelithiasis. Authors' stated limitations: a longer treatment period "would have provided insight into the durability of the effect of semaglutide"; follow-up was too short to monitor the effect of stopping, with weight regain noted between weeks 68 and 75; and "the enrolled trial population may limit the generalizability of the results", with more girls than boys, few participants from some racial and ethnic groups, eight with type 2 diabetes and one with overweight. Growth velocity, pubertal staging and bone mineral density are not among the outcomes reported.
- Senior author's account of the Pediatrics prescribing study. STAT, October 1, 2026. statnews.com. Read at source. First-person piece by a researcher on the study. States: "Among more than 3.5 million children ages 8-11 with obesity in our study, only 0.6% received a GLP-1 prescription", and of that figure, "This number is too low." States "a 310-fold increase in GLP-1 receptor agonist prescriptions for children ages 8-11 with obesity since 2019." States "Several drugs in this class are approved to treat obesity in adolescents 12 and older, but none are currently approved for younger children." States that broader use in younger children "is not justified without long-term data on how these medications impact growth and puberty." Cited for the study's headline figures and for the author's own stated position; the piece does not describe the study's design, data source or end year.
- Nutritional deficiency diagnoses and nutrition counselling among adolescent GLP-1 receptor agonist users. Childhood Obesity, 2026. DOI 10.1177/21532176261486979. journals.sagepub.com. Abstract and discussion read at source. Retrospective analysis of Inovalon administrative claims data from 2017 to 2022 covering over 100 million patients; 2,031 GLP-1RA users aged 10 to 17 meeting continuous enrolment criteria, followed for up to one year after initiation. 16.88% diagnosed with at least one nutritional deficiency or deficiency-related complication, reported as 16.8% in the Results section. Most common: vitamin D deficiency 12.4%, nutritional anaemia 1.55%, iron-deficiency anaemia 1.44%. "Only 23.3% had NT/C visit within 180 days", mean time to first visit 149 days. The discussion states the analysis "does not permit causal inference regarding the effects of GLP-1RA therapy or NT/C on nutritional outcomes", that claims-based codes may under-report subclinical deficiencies, and that the data cannot capture the content or quality of counselling.
- Peptide Decoding vendor price capture, October 10, 2026. peptidedecoding.com/prices. Our own data, counting one priced product at one seller as a listing. Semaglutide appears in 179 listings across 85 sellers, median $7.00 per mg among in-stock single vials. Method checked by reproducing the eloralintide figures published in our EloraTZP piece.
- American Academy of Pediatrics. Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity. Pediatrics, 2023. publications.aap.org. Mixed sourcing, stated. The definition of intensive health behaviour and lifestyle treatment is quoted from the guideline full text read at source: it "is most often effective when it occurs face-to-face, engages the whole family, and delivers at least 26 hours", and it "is foundational to COT and should continue longitudinally." The pharmacotherapy and surgery recommendations are cited via Healio's January 9, 2023 report of the guideline, because the treatment Key Action Statements sit beyond the retrievable portion of the full text and the Executive Summary page would not load. Per that report, clinicians should "offer weight loss pharmacotherapy as an adjunct to health behavior and lifestyle treatment for adolescents aged 12 years or older with obesity", and adolescents aged 13 or older with severe obesity "should be evaluated for metabolic and bariatric surgery". The Key Action Statement numbers, strength of recommendation and evidence grades were not retrieved and are not quoted.
Citing this page. Peptide Decoding. Are GLP-1 Drugs Safe for Teenagers? What the Trials Did Not Measure. Approval ages from product labelling; trial figures from STEP TEENS; WHO guidance of October 7, 2026; listing data from the October 10, 2026 capture. https://peptidedecoding.com/guides/glp1-teens